𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma

✍ Scribed by Elizabeth Eisenhauer; Ian Quirt; Joseph M. Connors; Jean Maroun; Jamey Skillings

Publisher
Springer US
Year
1985
Tongue
English
Weight
234 KB
Volume
3
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Multicenter phase II study of CyclOBEAP
Multicenter phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma
✍ Nozomi Niitsu; Masataka Okamoto; Mika Kohori; Sadao Aoki; Ikuo Miura; Masami Hir πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 169 KB

## Abstract We treated elderly patients (65–69 years) who had aggressive lymphoma with the CyclOBEAP regimen, and we studied the safety and efficacy of this treatment. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin 40 mg/m^2^ was given every 2 weeks in combinati

A phase II study of spirogermanium in pa
A phase II study of spirogermanium in patients with metastatic malignant melanoma
✍ Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 205 KB

The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc

Phase II study of spirogermanium in pati
Phase II study of spirogermanium in patients with advanced colorectal carcinoma
✍ Jaffer A. Ajani; Jack S. Faintuch; Roxann K. McClure; Bernard Levin; Bruce M. Bo πŸ“‚ Article πŸ“… 1986 πŸ› Springer US 🌐 English βš– 193 KB

Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/rn 2 (range 120-210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients